机构：[1]State Key Laboratory of Cardiovascular Disease, Heart Failure Center, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciencesand Peking Union Medical College, Beijing, China[2]Department of Cardiology, Henan Provincial People’s Hospital, Zhengzhou University People’s Hospital, Zhengzhou, China[3]Department of Cardiology, Central China Fuwai Hospital, Central China Fuwai Hospital of Zhengzhou University, Zhengzhou, China[4]Duke Clinical Research Institute,Durham, North Carolina, USA[5]Division of Cardiology, Duke University School of Medicine, Durham, North Carolina, USA[6]Division of Cardiology, University of California SanDiego, San Diego, California, USA[7]Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi, USA[8]Department of Cardiology, LanzhouUniversity Second Hospital, Lanzhou, China[9]Department of Cardiology, Hunan Provincial People’s Hospital, The First Affiliated Hospital of Hunan Normal University, HunanNormal University, Changsha, China[10]Department of Cardiology, Zhongda Hospital Affiliated to Southeast University, Nanjing, China[11]Department of Cardiology, NanjingDrum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China[12]Department of Cardiology, China-Japan Union Hospital of Jilin University, Changchun, China吉林大学中日联谊医院[13]Jilin Provincial Key Laboratory for Genetic Diagnosis of Cardiovascular Disease, Changchun, Jilin Province, China[14]Key Laboratory ofCardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Department of Cardiology, Qilu Hospital of ShandongUniversity, Jinan, China[15]State Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Key Laboratory forOrgan Failure Research, Ministry of Education of the People’s Republic of China, Guangzhou, China[16]Department of Cardiology, Xinqiao Hospital of Army MedicalUniversity, Chongqing, China[17]Department of Cardiology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China[18]Key Laboratory of MyocardialIschemia, Ministry of Education, Harbin Medical University, Harbin, China[19]Department of Cardiology, Institute of Cardiovascular Diseases, First Affiliated Hospital of DalianMedical University, Dalian, China大连医科大学附属第一医院[20]Department of Cardiology, First People’s Hospital of Yunnan Province, Kunming, China云南省第一人民医院心血管内科内科片[21]Department of Heart Failure, AffiliatedHospital of Chifeng College, Chifeng, China
Aims Heart failure (HF) remains a major public health problem with increasing prevalence in China. This study evaluated the clinical performance and quality measures for HF management to identify gaps in the standardization of care for patients hospitalized for HF in China. Methods and results Following the results of China-HF stage 1(2012-2015), the second stage of the China-HF was launched in 2017. Among 113 hospitals with >= 100 cases, the China-HF Stage II assessed the quality of care measures for HF and compared results with previous data in China and the US-based Get with The Guidelines-Heart Failure (GWTG-HF) registries. In total, 34 938 patients hospitalized with HF were enrolled from January 2017 to October 2020. Echocardiographic left ventricular function and natriuretic peptide test were performed in 93.7% and 93.0% of the cases, respectively. Adherence to standardized guidelines in China-HF stage II was higher than that in the China-HF stage I, but generally lower than GWTG-HF registry with 78.2% of eligible patients was prescribed oral diuretics, 78.7% renin-angiotensin-system inhibitors, and 82.2% beta-blockers. Implantable cardioverter-defibrillators and cardiac resynchronization devices were implanted in 3.9% and 14.6%, respectively. In contrast, the proportion of eligible patients discharged with spironolactone (87.8%) was higher than GWTG-HF. The median length of hospitalization was 9 (6, 12) days, and 938 (2.8%) patients died or withdrew from treatment during hospitalization. Conclusions Despite significant improvements in the use of guideline-recommended testing and therapy, there remain major gaps in quality of care for patients hospitalized for HF in China that are generally larger than gaps observed in the United States.
基金：
National Key Research and Development Program of China [2017YFC1308301, 2017YFC1308305]
第一作者机构：[1]State Key Laboratory of Cardiovascular Disease, Heart Failure Center, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciencesand Peking Union Medical College, Beijing, China
通讯作者：
通讯机构：[1]State Key Laboratory of Cardiovascular Disease, Heart Failure Center, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciencesand Peking Union Medical College, Beijing, China[*1]State Key Laboratory of Cardiovascular Disease, Heart Failure Center, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 167 Beilishi Road, 10037 Beijing, China
推荐引用方式(GB/T 7714)：
Yuhui Zhang,Chuanyu Gao,Stephen J. Greene,et al.Clinical performance and quality measures for heart failure management in China: the China-Heart Failure registry study[J].ESC HEART FAILURE.2023,10(1):342-352.doi:10.1002/ehf2.14184.
APA：
Yuhui Zhang,Chuanyu Gao,Stephen J. Greene,Barry H. Greenberg,Javed Butler...&Jian Zhang.(2023).Clinical performance and quality measures for heart failure management in China: the China-Heart Failure registry study.ESC HEART FAILURE,10,(1)
MLA：
Yuhui Zhang,et al."Clinical performance and quality measures for heart failure management in China: the China-Heart Failure registry study".ESC HEART FAILURE 10..1(2023):342-352
